Modified from Mller et al.29 The GLP-1 receptor (rGLP-1) belongs to the B family of G protein-coupled receptors and is expressed in the pancreas, gastrointestinal tract, central nervous system (CNS), kidneys, lungs and heart
The trials target distinct populations: obesity or overweight without type 2 diabetes (TRIUMPH-1), with type 2 diabetes (TRIUMPH-2), severe obesity with established cardiovascular disease (TRIUMPH-3), and obesity with knee osteoarthritis (TRIUMPH-4)
Marston, Eastern District of Pennsylvania Number of Cases: Approximately 2,947 pending cases (and growing rapidly) Defendants: Novo Nordisk and Eli Lilly Covered Drugs: Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Victoza, Saxenda, Trulicity Key Developments: August 15, 2025 - Landmark Ruling: Judge Marston ruled that gastroparesis claims require objective diagnostic testing (gastric emptying scan)
The serious side effects such as pancreatitis and kidney issues are rare across all options
However, a 57% reduction in renal events was observed compared to those receiving only GLP-1 RAs (114)
The semaglutide diet plan and tirzepatide diet plan both address this in detail